Correspondence 0001493152-25-004059 from Vivos Therapeutics, Inc. (VVOS)
Vivos Therapeutics, Inc.
Date: Jan. 29, 2025 · CIK: 0001716166 · Accession: 0001493152-25-004059
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-284399
Letter
VIA EDGAR Division of Corporation Finance Office of Life Sciences Re: Vivos Therapeutics, Inc. Registration Statement on Form S-1, as amended File No. 333-284399 Attention: Conlon Danberg
Dear Mr. Danberg:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Vivos Therapeutics, Inc. hereby requests acceleration of effectiveness of the above referenced Registration Statement so that it will become effective at 4:30 p.m. EST on Thursday, January 30, 2025, or as soon as practicable thereafter.
Very
truly yours,
/s/
Bradford Amman
Show Raw Text
CORRESP
1
filename1.htm
VIVOS
THERAPEUTICS, INC.
7921
Southpark Plaza, Suite 210
Littleton,
Colorado 80120
January
29, 2025
VIA
EDGAR
U.S.
Securities and Exchange Commission
Division
of Corporation Finance
Office
of Life Sciences
100
F Street, N.E.
Washington,
DC 20549
Re:
Vivos
Therapeutics, Inc.
Registration
Statement on Form S-1, as amended
File
No. 333-284399
Attention:
Conlon Danberg
Dear
Mr. Danberg:
Pursuant
to Rule 461 under the Securities Act of 1933, as amended, Vivos Therapeutics, Inc. hereby requests acceleration of effectiveness of the
above referenced Registration Statement so that it will become effective at 4:30 p.m. EST on Thursday, January 30, 2025, or as soon as
practicable thereafter.
Very
truly yours,
/s/
Bradford Amman
Bradford
Amman
Chief
Financial Officer
cc:
Ellenoff Grossman & Schole LLP